Navigation Links
Cobalis Expects to Report Phase III Top-Line Results in May

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced it has been informed by its independent contract research organization that it would need more time to combine Cobalis' three locked data bases into a single database before un-blinding and conducting the statistical analysis required to generate top-line results for Cobalis' twin pivotal Phase III Clinical Trials of PreHistin(TM) in seasonal allergic rhinitis. The Company anticipates reporting its top-line results later in May.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. Cobalis plans to seek FDA approval to market PreHistin over-the-counter in the US. For further information, visit www.cobalis.com

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and un
'"/>




Page: 1 2

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cobalis Expects Report Phase III Top Line Results May
(Date:4/16/2015)... 2015 A drug commonly taken to prevent seizures ... multiple sclerosis (MS), according to a study released today that ... Annual Meeting in Washington, DC , April ... people with MS experience at some point in their life ... carrying vision from the eye to the brain gets inflamed," ...
(Date:4/16/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Tuesday, April 21, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Diplomat Names Shannon M. Beltrand as New CISO 2
... TEMECULA, Calif., Nov. 17 Patient Safety Technologies, Inc. ... results. , "We are continuing to see strong year ... margins," stated Steven H. Kane, Chief Executive Officer of ... sales of safety sponges were comparable with revenues in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Research Small and Mid Cap Conference on Friday, November 20, 2009 ... general public are invited to listen to a live audio broadcast ... accessed at www.wbmd.com (in the Investor Relations ...
Cached Medicine Technology:Patient Safety Technologies Reports Third Quarter Results 2Patient Safety Technologies Reports Third Quarter Results 3Patient Safety Technologies Reports Third Quarter Results 4Patient Safety Technologies Reports Third Quarter Results 5Patient Safety Technologies Reports Third Quarter Results 6
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
(Date:4/17/2015)... Tallahassee, Fla. (PRWEB) April 17, 2015 ... percent of dental restoration units are made overseas by ... Commission. Additionally, domestic labs remain unregulated in more than ... , The National Association of Dental Laboratories ... campaign to raise awareness among patients about the consequences ...
(Date:4/17/2015)... Jacksonville, Fla. (PRWEB) April 17, 2015 ... Cancer Center have signed a partnership agreement designed to ... , The institutions have agreed to create a ... Anderson’s treatment protocols and translational research. Baptist MD Anderson ... of 2015, providing a single destination for highly coordinated, ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... Fat Pad Restoration on The Balancing Act on Lifetime TelevisionBOCA ... great doing it" is more than a tag line for ... is a leading expert and innovator in the science of ... a woman, she understands the emotional needs that many women ...
... Pharmakon introduced next generation of health ... quality natural liquid calcium & mineral supplement ... segments of athletes, women in pre and ... calcium supplementation. The innovative products of Aim ...
... the HR outsourcing marketplace, Empyrean Benefit Solutions is changing the status ... lower price. , ... Houston, TX (PRWEB) January 12, ... to grow by over 800% in annual revenue in their first ...
... employ comparative effectiveness research tools to address large, unwarranted variations ... benefits corporate spending. , ... Phoenixville, ... effectiveness data addresses large and unwarranted variations in corporate spending. ...
... SAN FRANCISCO, Jan. 12 Hiemstra Product Development, ... the debut of,hiQual, its proprietary electronic quality management ... the integration of hiQual, Hiemstra,s development team can ... the necessary documentation,required under ISO 13485:2003 and FDA ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
Cached Medicine News:Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 2Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development 2Health News:Acclarent, Inc. Closes $26 Million Financing 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: